Thorac Cardiovasc Surg 2005; 53(6): 341-345
DOI: 10.1055/s-2005-865760
Original Cardiovascular

© Georg Thieme Verlag KG Stuttgart · New York

Aspirin and Clopidogrel Taken Until 2 Days Prior to Coronary Artery Bypass Graft Surgery Is Associated with Increased Postoperative Drainage Loss

C. von Heymann1 , U. Redlich1 , M. Moritz1 , M. Sander1 , O. Vargas Hein1 , H. Grubitzsch2 , W. F. Konertz2 , 3 , C. Spies1 , 4
  • 1Department of Anesthesiology and Intensive Care Medicine, Charité - University Hospital Berlin, Berlin, Germany
  • 2Department of Cardiovascular Surgery, Charité - University Hospital Berlin, Berlin, Germany
  • 3Professor and Chair of the Department of Cardiovascular Surgery, Charité - University Hospital Berlin, Berlin, Germany
  • 4Professor and Chair of the Department of Anesthesiology and Intensive Care Medicine, Charité - University Hospital Berlin, Berlin, Germany
Weitere Informationen

Publikationsverlauf

Received December 9, 2004

Publikationsdatum:
28. November 2005 (online)

Abstract

Objective: Platelet aggregation inhibitors, such as aspirin and clopidogrel, are associated with increased bleeding in patients undergoing cardiac surgery with cardiopulmonary bypass. We investigated the impact of time between the last intake of aspirin and clopidogrel before CABG surgery and drainage loss, transfusion requirements and rate of reoperation. Patients and Methods: The records of patients who had coronary artery bypass graft surgery (CABG) were reviewed for intake of aspirin and clopidogrel within 7 days prior to surgery. Drainage loss, transfusion requirements and rate of reoperation for bleeding within 5 days after the operation, were recorded. Results: Out of 261 analysed patients, 225 patients (86.2 %) had no anti-platelet medication and 36 patients (13.8 %) were on aspirin and clopidogrel. Aspirin and clopidogrel, taken all until 2 days prior to operation, were associated with a significantly higher postoperative blood loss (1840 mL [1230 - 3710] vs. 280 mL [185 - 765], p = 0.005 for one day and 850 mL [345 - 1725] vs. 277 mL [165 - 778], p = 0.026, for 2 days prior to surgery). The trend showed that patients in the study group received more platelet concentrates (PC: 5.3 % vs. 13.9 %, p = 0.067). The rate of reoperation for bleeding was not different (p = 0.25). Conclusion: Aspirin and clopidogrel up to 2 days prior to CABG were associated with a significantly higher postoperative drainage loss.

References

  • 1 Yusuf S, Zhao F, Mehta S R, Chrolavicius S, Tognoni G, Fox K K. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
  • 2 Dörr G, Schmidt G, Gräfe M, Regitz-Zagrosek V, Fleck E. Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation.  J Cardiovasc Pharmacol. 2002;  39 523-532
  • 3 Yende S, Wunderink R G. Effect of clopidogrel on bleeding after coronary artery bypass surgery.  Crit Care Med. 2001;  29 2271-2275
  • 4 Ray J G, Deniz S, Olivieri A, Pollex E, Vermeulen M J, Alexander K S, Cain D J, Cybulsky I, Hamielec C M. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel.  BMC Cardiovasc Disord. 2003;  3 3
  • 5 Hongo R H, Ley J, Dick S E, Yee R R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.  J Am Coll Cardiol. 2002;  40 231-237
  • 6 Fox K A, Mehta S R, Peters R, Zhao F, Lakkis N, Gersh B J, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome. The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial.  Circulation. 2004;  110 1202-1208
  • 7 Chopra V, Marmur J D, Cavusoglu E. The role of clopidogrel in the management of patients with ischemic heart disease.  Cardiovasc Drugs Ther. 2003;  17 467-477
  • 8 Saw J, Topol E J, Steinhubl S R, Brennan D, Berger P B, Moliterno D J. CREDO Investigators. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention.  Am J Cardiol. 2004;  94 623-625
  • 9 Calafiore A M, Teodori G, Mezzetti A, Bosco G, Verna A M, Di Giammarco G, Lapenna D. Intermittent antegrade warm blood cardioplegia.  Ann Thorac Surg. 1995;  59 398-402
  • 10 Caplain H, Donat F, Gaut C, Necciari J. Pharmacokinetics of clopidogrel.  Semin Thromb Hemost. 1999;  25 (Suppl 2) 25-28
  • 11 Weber A A, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.  Br J Clin Pharmacol. 2001;  52 333-336
  • 12 Thebault J J, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel.  Semin Thromb Hemost. 1999;  25 (Suppl 2) 3-8
  • 13 Thebault J J, Kieffer G, Lowe G D, Nimmo W S, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.  Semin Thromb Hemost. 1999;  25 (Suppl 2) 9-14
  • 14 Jones H U, Muhlestein J B, Jones K W, Bair T L, Lavasani F, Sohrevardi M, Horne B D, Doty D, Lappe D L. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports.  Circulation. 2002;  106 (Suppl 1) I19-I22
  • 15 Pothula S, Sanchala V T, Nagappala B, Inchiosa Jr M A. The effect of preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery.  Anesth Analg. 2004;  98 4-10
  • 16 Patrono C. Aspirin as an antiplatelet drug.  N Engl J Med. 1994;  330 1287-1294
  • 17 Englberger L, Faeh B, Berdat P A, Eberli F, Meier B, Carrel T. Impact of clopidogrel in coronary artery bypass grafting.  Eur J Cardiothorac Surg. 2004;  26 96-101
  • 18 Ley S J. Quality care outcomes in cardiac surgery: the role of evidence-based practice.  AACN Clin Issues. 2001;  12 606-617
  • 19 Karabulut H, Toraman F, Evrenkaya S, Goksel O, Tarcan S, Alhan C. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery.  Eur J Cardiothorac Surg. 2004;  25 419-423
  • 20 Rawitscher R E, Jones J W, McCoy T A, Lindsley D A. A prospective study of aspirin's effect on red blood cell loss in cardiac surgery.  J Cardiovasc Surg. 1991;  32 1-7
  • 21 Karthik S, Grayson A D, McCarron E E, Pullan D M, Desmond M J. Re-exploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay.  Ann Thorac Surg. 2004;  78 527-534
  • 22 Tuman K J, McCarthy R J, O'Connor C J, McCarthy W E, Ivankovich A D. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery.  Anesth Analg. 1996;  83 1178-1184
  • 23 Reich D L, Patel G C, Vela-Cantos F, Bodian C, Lansman S. Aspirin does not increase homologous blood requirements in elective coronary bypass surgery.  Anesth Analg. 1994;  79 4-8
  • 24 Moulton M J, Creswell L L, Mackey M E, Cox J L, Rosenbloom M. Re-exploration for bleeding is a risk factor for adverse outcomes after cardiac operations.  J Thorac Cardiovasc Surg. 1996;  111 1037-1046

MD, DEAA Christian von Heymann

Department of Anesthesiology and Intensive Care Medicine
Charité - University Hospital Berlin
Charité Campus Mitte

Schumannstraße 20 - 21

10117 Berlin

Germany

Telefon: + 4930450531012

Fax: + 49 3 04 50 53 19 11

eMail: christian.von_heymann@charite.de